Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Rises By 11.4%

BioAtla, Inc. (NASDAQ:BCAB) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 4,400,000 shares, a growth of 11.4% from the December 15th total of 3,950,000 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is currently 3.9 days.

Analysts Set New Price Targets

Separately, HC Wainwright downgraded BioAtla from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th.

Institutional Trading of BioAtla

Institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC bought a new position in BioAtla in the 2nd quarter valued at $872,000. Scion Asset Management LLC bought a new position in BioAtla during the second quarter valued at about $869,000. Massachusetts Financial Services Co. MA increased its holdings in BioAtla by 5.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock worth $1,002,000 after buying an additional 28,133 shares during the last quarter. Bank of Montreal Can raised its position in BioAtla by 55.1% in the second quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock worth $554,000 after acquiring an additional 143,521 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in BioAtla in the third quarter valued at about $623,000. 77.23% of the stock is owned by hedge funds and other institutional investors.

BioAtla Price Performance

Shares of NASDAQ BCAB traded up $0.01 during trading on Friday, hitting $0.49. The stock had a trading volume of 373,650 shares, compared to its average volume of 1,483,387. The firm has a fifty day moving average of $1.17 and a two-hundred day moving average of $1.57. The company has a market capitalization of $23.84 million, a PE ratio of -0.29 and a beta of 1.17. BioAtla has a 12 month low of $0.45 and a 12 month high of $4.02.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.12. The firm had revenue of $11.00 million during the quarter. During the same period last year, the firm earned ($0.70) earnings per share. On average, equities analysts expect that BioAtla will post -1.46 earnings per share for the current fiscal year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.